Since all 5 LOX isoforms were elevated in human and murine iCCA, we sought to assess the impact of pan-LOX inhibition on iCCA tumorigenesis with the irreversible small molecule pan-LOX inhibitor PXS-5505 in URCCA4.3 tumor-bearing mice, which achieved robust plasma levels and target engagement when administered in the diet (Supplemental methods, supplemental Figure S8B, C, http://links.lww.com/HC9/A993). This evidence concerns the gene PRRT2 and neoplasm.